"You're Just Trading One Addiction for Another": Debunking the Myths That Keep Families From Choosing MAT
Family members researching MAT often hit the same myths. Here's what the research actually shows about medication-assisted treatment for opioid addiction.
A father in Ohio once told researchers running a NIDA-funded study that he'd rather watch his son detox "the hard way" than let him take a medication he associated with street corners and needle exchanges. Eight months later, his son was dead of a fentanyl overdose. That story, recounted in testimony before a congressional panel on opioid policy, isn't rare. It's the predictable outcome of a set of myths about medication-assisted treatment that have outlived the science disproving them.
Families researching help for a loved one run into these myths constantly — from well-meaning relatives, from support group members, sometimes from treatment staff who trained decades ago. The myths aren't just wrong. They're dangerous. Patients who leave methadone or buprenorphine treatment against medical advice face overdose death rates several times higher than those who stay in care, according to research published in JAMA Psychiatry. Yet fewer than one in five people with opioid use disorder in the United States receive medication treatment at all, per SAMHSA's National Survey on Drug Use and Health.
This piece isn't a repeat explainer of how methadone or buprenorphine work in the body — that ground has been covered elsewhere. It's a myth-by-myth breakdown aimed at the specific objections family members raise when they're deciding whether to support, discourage, or actively block a loved one from starting medication treatment. If your family is comparing opioid addiction treatment programs and someone at the kitchen table is saying "but isn't that just substituting one drug for another," this is for you.
Myth: "Medication Just Replaces One Addiction With Another"
This is the single most persistent myth in addiction medicine, and it survives because it sounds intuitively true. Someone dependent on heroin starts taking methadone or buprenorphine daily — doesn't that just swap the substance?
Addiction medicine draws a hard line between dependence and addiction. Dependence means the body has adapted to a substance and experiences withdrawal without it — true of many prescribed medications, including blood pressure drugs and antidepressants. Addiction is compulsive use despite harm: lost jobs, ruined relationships, legal consequences, risk of death.
Methadone and buprenorphine, taken as prescribed, stabilize brain chemistry without producing the euphoric high that drives compulsive use. A 2018 review in described this distinction as the difference between "restoring normal function" and "chasing intoxication." People on stable doses of these medications drive, work, parent, and function — something rarely true during active .
The World Health Organization lists methadone and buprenorphine on its Model List of Essential Medicines specifically because of this distinction. That's not a harm-reduction compromise. It's a formal recognition that these medications treat a chronic brain disease the same way insulin treats diabetes.
Myth: "Real Recovery Means Total Abstinence From All Substances"
This belief is baked deeply into American recovery culture, largely because of the dominance of 12-step language in popular understanding of addiction. But it doesn't hold up against outcome data.
A landmark study following patients after opioid overdose in Massachusetts found that those treated with methadone or buprenorphine had a 50% or greater reduction in mortality over the following year compared to those who received no medication or only detox. Detox-only approaches — the ones that satisfy the abstinence ideal most cleanly — showed the worst survival outcomes of any treatment pathway studied.
Some families push back here: shouldn't the goal be a life completely free of medication? For some patients, tapering off medication eventually is realistic and appropriate, done slowly under medical supervision. For others, especially those with years of severe opioid use disorder, staying on medication indefinitely — the way someone might stay on thyroid medication for life — produces the best long-term outcomes. Neither path is a lesser form of recovery.
Myth: "MAT Is Just for People Who Aren't Serious About Quitting"
Family members sometimes interpret a loved one's interest in medication treatment as evidence they're looking for an easy way out — a way to keep using without consequences. This misunderstanding usually comes from confusing MAT with the unsupervised, illicit use of these same medications, which does happen and does look different from clinical treatment.
Properly administered MAT involves regular counseling, drug screening, and dosing that's titrated by a physician specifically to block cravings and prevent withdrawal — not to produce a high. Patients in stable methadone programs report the opposite of "getting away with something." Daily clinic visits, especially in early treatment, require more discipline and structure than many other treatment modalities.
Research from the American Society of Addiction Medicine found retention rates in buprenorphine treatment at 12 months were substantially higher than retention in abstinence-only programs — largely because medication reduces the physiological drive to relapse that undermines willpower-based approaches. Families who frame medication as "cheating" often unintentionally push loved ones toward the higher-risk, higher-relapse path.
Myth: "If They Need Medication, the Underlying Problem Isn't Being Treated"
This myth assumes medication and therapy are competing approaches, when the evidence points the other way. Federal treatment guidelines from SAMHSA explicitly define MAT as the combination of medication with counseling and behavioral therapies — not medication alone.
The medication addresses the neurobiological piece: the intense cravings and withdrawal symptoms that hijack decision-making. Counseling addresses the behavioral, relational, and psychological pieces — the triggers, trauma histories, and life patterns that surround the addiction. Treating one without the other tends to produce worse outcomes than treating both together, according to a Cochrane systematic review of opioid treatment approaches.
Families can play a real role here by asking treatment centers direct questions: What counseling is included alongside medication? How often are dosages reviewed? Is there a plan for family involvement or education? Programs that offer medication with no accompanying therapy component are missing half the model — and that's a fair thing to flag when comparing programs side-by-side.
Myth: "Methadone Clinics Are Dangerous, Chaotic Places"
Older cultural depictions of methadone clinics — often filmed in under-resourced urban settings decades ago — still shape how families picture treatment. That image doesn't reflect how regulated opioid treatment programs operate today.
In the U.S., opioid treatment programs dispensing methadone are certified by SAMHSA and regulated by the DEA, with strict protocols for dosing, urine screening, and take-home privileges tied to demonstrated stability. Buprenorphine, meanwhile, can now be prescribed from a regular doctor's office or through telehealth following changes to federal prescribing rules — removing much of the clinic-based stigma entirely.
That said, quality varies between facilities, and families should still ask questions before committing: What's the counselor-to-patient ratio? Is there a physician on-site or on-call? What happens if a dose is missed? A rushed, poorly staffed program can undercut even the best medication — which is exactly why comparing accredited centers matters more than assuming all programs are equivalent.
Myth: "Insurance Won't Cover It, So It's Not Worth Pursuing"
Coverage gaps for MAT were a real barrier for years, and some families still assume medication treatment is out of reach financially. The landscape has shifted substantially. The Affordable Care Act classified substance use disorder treatment, including MAT, as an essential health benefit for marketplace plans. Medicaid — which covers a significant share of opioid use disorder treatment nationally — is required in most states to cover at least one form of MAT medication.
Gaps still exist, particularly around prior authorization requirements and provider shortages in rural areas. But "my insurance won't cover it" is worth verifying directly with a treatment center's admissions team rather than assuming it upfront. Many programs have staff specifically trained to sort out coverage and identify state-funded alternatives when private insurance falls short.
What This Means for Your Family's Decision
If you're the person doing the research — reading clinic websites at midnight, cross-referencing reviews, trying to figure out what's real and what's outdated dogma — the myths above are worth naming out loud in family conversations. Addiction treatment decisions often get derailed not by lack of access, but by disagreement among family members about what "real" treatment looks like.
It helps to separate two questions: what does the research say works, and what does our family believe should work. Those aren't always the same, and it's worth sitting with that gap rather than pretending it doesn't exist. A loved one's life may depend on which side of that gap the family lands on.
If you're unsure where to start, taking a short assessment can help clarify what level of care and what treatment approach might fit your loved one's specific situation before you start calling clinics.
Frequently Asked Questions
Is medication-assisted treatment considered "real" recovery by medical professionals?
Yes. Major medical bodies — including the American Society of Addiction Medicine, the American Medical Association, and the World Health Organization — classify MAT as the standard of care for opioid use disorder, not a lesser or alternative form of treatment.
How long does someone typically stay on medication like methadone or buprenorphine?
There's no universal timeline. Some patients taper off within a year or two under medical supervision; others remain on maintenance doses for many years. Research consistently shows longer retention in treatment correlates with better outcomes, so tapering too early carries real relapse risk.
Can my loved one work or drive normally while on MAT?
Most patients on a stable, medically supervised dose can drive, work, and carry out daily responsibilities normally. The medication is designed to eliminate withdrawal and cravings, not to sedate or impair — unlike active opioid use.
What if my family member has tried MAT before and relapsed anyway?
A past relapse on medication doesn't mean MAT failed or won't work this time. Dosage, counseling intensity, and life circumstances all affect outcomes, and many patients need adjustments or a different combination of medication and therapy before finding what's sustainable.
How do we find a treatment center that combines medication with proper counseling support?
Ask directly about counselor-to-patient ratios, therapy session frequency, and physician availability during intake calls. Our center directory allows families to compare accredited programs and their specific MAT protocols before making a decision.
The myths around medication-assisted treatment persist not because the evidence is unclear, but because outdated cultural narratives are harder to unlearn than new facts are to learn. Families who take the time to separate the two — often under enormous emotional pressure and on a painfully short timeline — give their loved one a real shot at the outcome the data actually supports: staying alive long enough to keep trying.
RA
Written by
Rehab-Atlas Editorial Team
Our editorial team consists of clinical specialists, addiction counselors, and healthcare writers dedicated to providing accurate, evidence-based information.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment decisions.
Looking for opioid treatment that fits?
Centers vary widely on MAT, detox, and aftercare. The assessment surfaces ones that match.
